1
|
|
2
|
Coopmans EC, van Meyel SWF, van der Lely AJ, Neggers SJCMM. The position of combined medical treatment in acromegaly. ARCHIVES OF ENDOCRINOLOGY AND METABOLISM 2019; 63:646-652. [PMID: 31939490 PMCID: PMC10522231 DOI: 10.20945/2359-3997000000195] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/03/2019] [Accepted: 11/19/2019] [Indexed: 11/23/2022]
Abstract
Advances in combination medical treatment have offer new perspectives for acromegaly patients with persistent disease activity despite receiving the available medical monotherapies. The outcomes of combination medical treatment may reflect both additive and synergistic effects. This review focuses on combination medical treatment and its current position in acromegaly, based on clinical studies evaluating the efficacy and safety of combined medical treatment(s) and our own experiences with combination therapy. Arch Endocrinol Metab. 2019;63(6):646-52.
Collapse
Affiliation(s)
- Eva C. Coopmans
- Section EndocrinologyPituitary Center RotterdamErasmus University Medical Center RotterdamRotterdamNetherlandsDepartment of Medicine, Section Endocrinology, Pituitary Center Rotterdam, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Sebastiaan W. F. van Meyel
- Section EndocrinologyPituitary Center RotterdamErasmus University Medical Center RotterdamRotterdamNetherlandsDepartment of Medicine, Section Endocrinology, Pituitary Center Rotterdam, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Aart J van der Lely
- Section EndocrinologyPituitary Center RotterdamErasmus University Medical Center RotterdamRotterdamNetherlandsDepartment of Medicine, Section Endocrinology, Pituitary Center Rotterdam, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Sebastian J. C. M. M. Neggers
- Section EndocrinologyPituitary Center RotterdamErasmus University Medical Center RotterdamRotterdamNetherlandsDepartment of Medicine, Section Endocrinology, Pituitary Center Rotterdam, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
| |
Collapse
|
3
|
Coopmans EC, Muhammad A, van der Lely AJ, Janssen JAMJL, Neggers SJCMM. How to Position Pasireotide LAR Treatment in Acromegaly. J Clin Endocrinol Metab 2019; 104:1978-1988. [PMID: 30608534 DOI: 10.1210/jc.2018-01979] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Accepted: 12/28/2018] [Indexed: 02/13/2023]
Abstract
CONTEXT Pasireotide long-acting release (LAR) is a somatostatin multireceptor ligand, and in the current consensus criteria pasireotide LAR is considered the second-line medical treatment for acromegaly. We present in this article our recommendations to define the position of pasireotide LAR in the treatment of acromegaly and provide recommendations for the management of pasireotide-induced hyperglycemia. EVIDENCE ACQUISITION Our recommendations are based on our experiences with the pasireotide LAR and pegvisomant (PEGV) combination study and the available basic or clinical articles published in peer-reviewed international journals on pasireotide LAR and acromegaly. EVIDENCE SYNTHESIS In accordance with the current consensus criteria, we recommend pasireotide LAR monotherapy as a second-line therapy in young patients who show tumor growth during first-generation somatostatin receptor ligand (SRL) therapy and in patients who show tumor growth during PEGV therapy. In addition, we recommend pasireotide LAR monotherapy in patients with headache not responsive to first-generation SRL therapy and in patients who experience side effects or are intolerant to PEGV monotherapy. In contrast to the current consensus criteria, we recommend considering combination therapy with pasireotide LAR and PEGV as third-line treatment in patients without diabetes at low PEGV dosages (≤80 mg/week) and in patients with tumor growth or symptoms of active acromegaly during first-generation SRL and PEGV combination therapy. With respect to pasireotide-induced hyperglycemia, we recommend a more liberal strategy of blood glucose monitoring during pasireotide treatment. CONCLUSIONS In contrast to the current consensus criteria, we recommend a more reluctant use of pasireotide LAR therapy for the treatment of acromegaly.
Collapse
Affiliation(s)
- Eva C Coopmans
- Department of Internal Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, CB Rotterdam, Netherlands
| | - Ammar Muhammad
- Department of Internal Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, CB Rotterdam, Netherlands
| | - Aart J van der Lely
- Department of Internal Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, CB Rotterdam, Netherlands
| | - Joseph A M J L Janssen
- Department of Internal Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, CB Rotterdam, Netherlands
| | - Sebastian J C M M Neggers
- Department of Internal Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, CB Rotterdam, Netherlands
| |
Collapse
|
4
|
Ikegami T. Hydrophilic interaction chromatography for the analysis of biopharmaceutical drugs and therapeutic peptides: A review based on the separation characteristics of the hydrophilic interaction chromatography phases. J Sep Sci 2019; 42:130-213. [DOI: 10.1002/jssc.201801074] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2018] [Revised: 11/17/2018] [Accepted: 11/18/2018] [Indexed: 12/13/2022]
Affiliation(s)
- Tohru Ikegami
- Faculty of Molecular Chemistry and Engineering; Kyoto Institute of Technology; Kyoto Japan
- Institute of Pharmaceutical Sciences; Pharmaceutical (Bio-) Analysis; Eberhard-Karls Universität Tübingen; Tübingen Germany
| |
Collapse
|
5
|
Tong Z, Atsriku C, Yerramilli U, Wang X, Li Y, Reyes J, Fan B, Yang H, Hoffmann M, Surapaneni S. Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans. Xenobiotica 2018; 49:200-210. [PMID: 29320949 DOI: 10.1080/00498254.2018.1425511] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
1. The absorption, distribution, metabolism and excretion of enasidenib were studied following a single oral dose of [14C]enasidenib to rats (10 mg/kg; 100 μCi/kg) and healthy volunteers (100 mg; 318 nCi). 2. Enasidenib was readily absorbed, extensively metabolized and primarily eliminated via the hepatobiliary pathway. Enasidenib-derived radioactivity was widely distributed in rats. Excretion of radioactivity was approximately 95-99% of the dose from rats in 168 h post-dose and 82.4% from human volunteers in 504 h post-dose. In rat bile, approximately 35-42% of the administered dose was recovered, with less than 5% of the dose excreted as the parent drug. Renal elimination was a minor pathway, with <12% of the dose excreted in rat urine and <10% of the dose excreted in human urine. 3. Enasidenib was the prominent radioactive component in rat and human systemic circulation. Enasidenib was extensively metabolized in rats and human volunteers through N-dealkylation, oxidation, direct glucuronidation and combinations of these pathways. Glucuronidation was the major metabolic pathway in rats while N-dealkylation was the prominent metabolic pathway in human volunteers. All human metabolites were detected in rats.
Collapse
Affiliation(s)
- Zeen Tong
- a Nonclinical Development , Celgene Corporation , Summit , NJ , USA
| | | | - Usha Yerramilli
- a Nonclinical Development , Celgene Corporation , Summit , NJ , USA
| | - Xiaomin Wang
- a Nonclinical Development , Celgene Corporation , Summit , NJ , USA
| | - Yan Li
- b Clinical Pharmacology , Celgene Corporation , Summit , NJ , USA , and
| | - Josephine Reyes
- b Clinical Pharmacology , Celgene Corporation , Summit , NJ , USA , and
| | - Bin Fan
- c DMPK/Clinical Pharmacology , Agios Pharmaceutical , Cambridge , MA , USA
| | - Hua Yang
- c DMPK/Clinical Pharmacology , Agios Pharmaceutical , Cambridge , MA , USA
| | - Matthew Hoffmann
- a Nonclinical Development , Celgene Corporation , Summit , NJ , USA
| | | |
Collapse
|
6
|
Tong Z, Atsriku C, Yerramilli U, Wang X, Nissel J, Li Y, Surapaneni S. Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans. Xenobiotica 2017; 49:43-53. [DOI: 10.1080/00498254.2017.1413718] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Zeen Tong
- Nonclinical Development, Celgene Corporation, Summit, NJ, USA and
| | | | - Usha Yerramilli
- Nonclinical Development, Celgene Corporation, Summit, NJ, USA and
| | - Xiaomin Wang
- Nonclinical Development, Celgene Corporation, Summit, NJ, USA and
| | - Jim Nissel
- Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA
| | - Yan Li
- Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA
| | | |
Collapse
|
7
|
Suri A, Pusalkar S, Li Y, Prakash S. Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK-700) in Healthy Male Subjects: A Phase 1, Open-Label, Single-Dose Study. Clin Pharmacol Drug Dev 2016; 5:180-7. [DOI: 10.1002/cpdd.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Ajit Suri
- Millennium Pharmaceuticals; Inc; a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge MA USA
| | - Sandeepraj Pusalkar
- Millennium Pharmaceuticals; Inc; a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge MA USA
| | - Yuexian Li
- Millennium Pharmaceuticals; Inc; a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge MA USA
| | - Shimoga Prakash
- Millennium Pharmaceuticals; Inc; a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge MA USA
| |
Collapse
|
8
|
|
9
|
Fu Y, Li W, Flarakos J, Tse FL. Quantitative analysis of pasireotide (SOM230), a cyclic peptide, in monkey plasma using liquid chromatography in combination with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1008:242-249. [DOI: 10.1016/j.jchromb.2015.11.025] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Revised: 11/07/2015] [Accepted: 11/15/2015] [Indexed: 10/22/2022]
|
10
|
Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats. Toxicol Appl Pharmacol 2015; 286:224-33. [PMID: 25981165 DOI: 10.1016/j.taap.2015.05.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2015] [Revised: 04/30/2015] [Accepted: 05/03/2015] [Indexed: 12/14/2022]
Abstract
The somatostatin analog pasireotide and the 11β-hydroxylase inhibitor osilodrostat (LCI699) reduce cortisol levels by distinct mechanisms of action. There exists a scientific rationale to investigate the clinical efficacy of these two agents in combination. This manuscript reports the results of a toxicology study in rats, evaluating different doses of osilodrostat and pasireotide alone and in combination. Sixty male and 60 female rats were randomized into single-sex groups to receive daily doses of pasireotide (0.3mg/kg/day, subcutaneously), osilodrostat (20mg/kg/day, orally), osilodrostat/pasireotide in combination (low dose, 1.5/0.03mg/kg/day; mid-dose, 5/0.1mg/kg/day; or high dose, 20/0.3mg/kg/day), or vehicle for 13weeks. Mean body-weight gains from baseline to Week 13 were significantly lower in the pasireotide-alone and combined-treatment groups compared to controls, and were significantly higher in female rats receiving osilodrostat monotherapy. Osilodrostat and pasireotide monotherapies were associated with significant changes in the histology and mean weights of the pituitary and adrenal glands, liver, and ovary/oviduct. Osilodrostat alone was associated with adrenocortical hypertrophy and hepatocellular hypertrophy. In combination, osilodrostat/pasireotide did not exacerbate any target organ changes and ameliorated the liver and adrenal gland changes observed with monotherapy. Cmax and AUC0-24h of osilodrostat and pasireotide increased in an approximately dose-proportional manner. In conclusion, the pasireotide and osilodrostat combination did not exacerbate changes in target organ weight or toxicity compared with either monotherapy, and had an acceptable safety profile; addition of pasireotide to the osilodrostat regimen may attenuate potential adrenal gland hyperactivation and hepatocellular hypertrophy, which are potential side effects of osilodrostat monotherapy.
Collapse
|
11
|
Tse S, Leung L, Raje S, Seymour M, Shishikura Y, Obach RS. Disposition and Metabolic Profiling of [14C]Cerlapirdine Using Accelerator Mass Spectrometry. Drug Metab Dispos 2014; 42:2023-32. [DOI: 10.1124/dmd.114.059675] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
|
12
|
Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, Lasher J, Hughes G, Hu K, Shen G, Reséndiz KH, Giannone V, Beckers A. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open-label, phase I study. J Clin Pharmacol 2014; 54:1308-17. [DOI: 10.1002/jcph.326] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2014] [Accepted: 05/02/2014] [Indexed: 12/16/2022]
Affiliation(s)
| | - Jens Bollerslev
- Oslo University Hospital; Section of Specialized Endocrinology, Medical Clinic B and Faculty of Medicine, University of Oslo; Oslo Norway
| | - Ayman M. Arafat
- Department of Endocrinology; Diabetes and Nutrition, Charité-University Medicine Berlin, Campus Benjamin Franklin; Berlin Germany
| | - Jochen Schopohl
- Medizinische Klinik IV; Campus Innenstadt, University of Munich; Munich Germany
| | - Omar Serri
- CHUM, Notre-Dame Hospital; Montreal Quebec Canada
| | - Laurence Katznelson
- Division of Endocrinology and Metabolism; Stanford University School of Medicine; Stanford CA USA
| | - Janet Lasher
- Novartis Pharmaceuticals Corporation; East Hanover NJ USA
| | - Gareth Hughes
- Novartis Pharmaceuticals Corporation; East Hanover NJ USA
| | - Ke Hu
- Novartis Pharmaceuticals Corporation; East Hanover NJ USA
| | - George Shen
- Novartis Pharmaceuticals Corporation; East Hanover NJ USA
| | | | | | - Albert Beckers
- CHU de Liège; Domaine Universitaire du Sart-Tilman Liège; Liège Belgium
| |
Collapse
|
13
|
Kornberger R, Ting LSL, Tripathi AP, Rodrigues H, Nesheiwat D, Passos VQ, Hu K. Effect of verapamil on the pharmacokinetics of pasireotide in healthy volunteers. J Clin Pharmacol 2014; 54:1263-71. [PMID: 24788408 DOI: 10.1002/jcph.325] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Accepted: 03/18/2014] [Indexed: 11/11/2022]
Abstract
We evaluated the drug-drug interaction between pasireotide SC and verapamil, a known P-glycoprotein inhibitor. Subjects received pasireotide SC (single dose, 600 μg) on day 1, and samples for pharmacokinetics evaluation were collected from days 1 to 8. Subjects received an oral dose of verapamil 240 mg/d for 10 days (days 15-24). On day 18, subjects also received pasireotide SC 600 μg. Pharmacokinetic sampling for pasireotide SC and verapamil was done during days 18 to 25 and days 15 to 21, respectively. Safety evaluations were performed throughout the study period, including a 30-day post-treatment follow-up. Pharmacokinetic profiles of pasireotide SC alone and in combination with verapamil sustained-release (SR) were superimposable with the geometric mean ratios (90% confidence interval [CI]) of 0.98 (0.91-1.06) for C(max), 0.97 (0.90-1.04) for AUC(last), and 0.98 (0.92-1.05) for AUC(inf). Exploratory analyses showed a 17% (90% CI, 0.72-0.94) reduction in C(trough) and 31% (0.58-0.82) reduction in C(max) (8 hours post-dose) for verapamil SR with pasireotide SC versus verapamil alone. Pasireotide SC with or without verapamil was well tolerated. In conclusion, there was no change in the rate of pasireotide absorption and elimination or extent of exposure following concomitant administration with verapamil.
Collapse
|